What Is Entyvio?

Entyvio (vedolizumab) is a prescription medication known as an integrin receptor antagonist. Entyvio is indicated for inflammatory bowel disorders such as Crohn’s disease and ulcerative colitis.

Entyvio is an antibody that helps reduce inflammation in the gut. It is used in patients who suffer from moderate to severe ulcerative colitis and moderate to severe Crohn’s disease. 

Entyvio is administered as an intravenous infusion over 30 minutes, and it is recommended to be administered by a healthcare professional for monitoring purposes. Patients must be observed during the treatment and when the infusion is complete.

Before initiation of Entyvio, patients must be up to date on all immunizations.

剂量信息

Entyvio comes in a 300 mg single-dose vial. The recommended dose discussed below pertains to both ulcerative colitis and Crohn’s disease.

It is recommended that 300 mg be infused intravenously over 30 minutes at zero, two, and six weeks. It should be administered every 8 weeks thereafter. By week 14, if the patient does not see a therapeutic benefit, Entyvio should be discontinued.

Entyvio should be infused by a healthcare professional and monitored for anaphylaxis. Entyvio is diluted in 0.9% sodium chloride or lactated Ringers. After dilution, Entyvio is stable for 12 hours at room temperature and 24 hours when refrigerated.

This medication is usually ordered by the doctor and sent to the doctor’s office to be administered. Hypersensitivity or infusion reactions may occur during administration, so a healthcare professional must administer this medication. 

It has also been reported that this medication causes upper respiratory tract infections. Before administering this medication, it is necessary to be up to date on vaccinations. Before administering Entyvio, report all medications taken in case of a drug interaction.

Entyvio is not recommended for patients experiencing infections. Doctors should administer it after infections have been controlled.